Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation - Takeaways - MDSpire

Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation

  • By

  • Tingyu Su

  • Fan Jiang

  • Jianjun Gao

  • Xiubin Li

  • Hongmei Cheng

  • Yang Wang

  • June 8, 2026

  • 0 min

Share

  • 1

    Kidney renal clear cell carcinoma (KIRC) has a poor prognosis, influenced by genomic alterations and immune microenvironment disorders.

  • 2

    CRHBP was identified as a core downregulated prognostic biomarker in KIRC, associated with favorable survival predictive value.

  • 3

    The study confirmed the causal risk effect of UCN2 on KIRC, which negatively correlates with tumor angiogenesis and hypoxia.

  • 4

    Dabrafenib was screened as a promising candidate drug targeting the CRHBP/UCN2 axis with significant binding affinity.

  • 5

    The CRHBP-UCN2 axis plays a critical role in regulating KIRC prognosis and immune microenvironment remodeling.

Original Source(s)

Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation

  • by Tingyu Su, Fan Jiang, Jianjun Gao, Xiubin Li, Hongmei Cheng, Yang Wang

  • June 8, 2026

Related Content

Cadonilimab in the treatment of advanced metastatic soft tissue clear cell sarcoma achieved complete remission: a case report

A multi-task deep learning framework for simultaneous prediction of microsatellite instability and tumor mutational burden in gastric cancer from histopathological images

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial